Ignite Creation Date:
2025-12-24 @ 12:02 PM
Ignite Modification Date:
2026-01-25 @ 3:56 AM
Study NCT ID:
NCT02588261
Status:
TERMINATED
Last Update Posted:
2024-12-10
First Post:
2015-10-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-11
Start Date Type:
ACTUAL
Primary Completion Date:
2017-12-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-12-21
Completion Date Type:
ACTUAL
First Submit Date:
2015-10-26
First Submit QC Date:
None
Study First Post Date:
2015-10-27
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-10
Results First Submit QC Date:
None
Results First Post Date:
2019-02-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-22
Last Update Post Date:
2024-12-10
Last Update Post Date Type:
ACTUAL